Narjust Duma, MD, was recently named Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine at Dana-Farber Cancer Institute/Harvard Medical School. In her role at the Cancer Care Equity Program, Dr. Duma will develop strategies to diminish health-care disparities and to enhance the delivery of cancer care to the greater Boston community.
Narjust Duma, MD
Dr. Duma will continue her clinical practice as a thoracic oncologist with a particular focus on women with lung cancer. Her research activities center on the study of lung cancer in young women and the impact of the disease on their physical and psychological well-being.
Dr. Duma is currently Assistant Professor of Medicine at the University of Wisconsin Madison and the University of Wisconsin Carbone Cancer Center. She graduated summa cum laude from the Universidad Católica Nordestana Medical School in the Dominican Republic, after which she completed her internal medicine residency at Rutgers New Jersey Medical School and her hematology and medical oncology fellowship at the Mayo Clinic in Rochester, Minnesota. Dr. Duma was selected by her peers as one of the 2018–2019 chief hematology and medical oncology fellows.
Focus on Discrimination in Medical Education and Medicine
Dr. Duma is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) study, which is thus far the largest evaluation of sexual dysfunction in women with lung cancer. In addition to her clinical interests, she is a renowned advocate and researcher in gender equity and balance in medicine and the founder and head of the Duma Lab, a research group concerned with social justice and cancer care health disparities.
Dr. Duma’s numerous awards include the 2018 Resident of the Year Award by the National Hispanic Medical Association, the Mayo Brothers Distinguished Fellowship award (considered the highest trainee honor in the Mayo Clinic School of Graduate Medical Education), and the 2020 Rising Star award by the LEAD national conference for women in hematology and oncology.